Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamics and tracer distribution of Tilmanocept for sentinel lymph node detection in early-stage breast cancer
2019-002597-32Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Nov 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of technetium tc 99m tilmanocept in breast cancer (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Time to identification of first lymph node. Started Nov 2019; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002597-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002597-32.